Fig. 3: FAK inhibition reduces primary and secondary sphere formation across all molecular phenotypes in patient samples.
From: FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity
a FAK inhibition with 0.5 μM VS4718 reduces primary mammosphere formation in 16 ER+/PR+/HER2− patient samples. b 0.5 μM VS4718 and 0.1 μM Lapatinib reduced primary MFE in four ER−/PR−/HER2+ patient samples. c 0.5 μM VS4718 and 0.1 μM Paclitaxel reduced primary MFE in six ER−/PR−/HER2− patient samples. Each patient had a minimum of six technical replicate values for MFE. d Graph demonstrating that FAK inhibition reduces mammosphere self-renewal in eight ER+/PR+/HER2− samples. Data in (a–d) analysed using Two-way ANOVA with post hoc Tukeys test. e Graph demonstrating that FAK inhibition in ER negative patient samples reduces mammosphere self-renewal. Unpaired two-tailed t-test. (ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001). All error bars represent mean + SEM. Photomicrographs taken at ×40 magnification of (f) primary patient mammosphere after VS4718 treatment (g) secondary mammosphere in DMSO group with 50 µM scale bars.
